Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.neclife.com | |
Market Cap | 336.84 Cr. | |
Enterprise Value(EV) | 1,112.41 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.72 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.17 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 47.27 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 0.32 | Calculated using Price: 15.16 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 22.43 Cr. | 224,260,970 Shares |
FaceValue | 1 | |
Company Profile | ||
Nectar Lifesciences (NecLife) incorporated in 1995, is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms. The company was previously known as Surya Medicare and is is promoted by Sanjiv Goyal. |
1 Day |
|
+3.84% |
1 Week |
|
-7.11% |
1 Month |
|
-12.37% |
3 Month |
|
-40.20% |
6 Month |
|
-27.46% |
1 Year |
|
-37.87% |
2 Year |
|
-18.93% |
5 Year |
|
-42.68% |
10 Year |
|
-3.13% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 6.92 | 7.17 | 5.78 | 5.64 | 5.06 | 4.40 | 2.84 | -6.67 | 2.33 | |
Return on Capital Employed (%) | 12.24 | 11.58 | 9.95 | 9.73 | 9.13 | 10.29 | 8.32 | 1.41 | 5.77 | |
Return on Assets (%) | 2.66 | 2.70 | 2.14 | 2.15 | 1.97 | 1.75 | 1.19 | -2.93 | 1.05 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 927 | 958 | 954 | 1,007 | 1,059 | 1,105 | 1,136 | 1,062 | 1,088 | 1,069 | |
Non Curr. Liab. | 341 | 397 | 362 | 296 | 356 | 300 | 249 | 126 | 296 | 264 | |
Curr. Liab. | 1,126 | 1,156 | 1,240 | 1,279 | 1,309 | 1,300 | 1,248 | 1,187 | 1,004 | 944 | |
Minority Int. | |||||||||||
Equity & Liab. | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,376 | 2,388 | 2,278 | |
Non Curr. Assets | 1,157 | 1,106 | 1,092 | 1,085 | 1,063 | 1,036 | 1,018 | 1,137 | 1,033 | 1,001 | |
Curr. Assets | 1,237 | 1,369 | 1,464 | 1,496 | 1,661 | 1,669 | 1,615 | 1,239 | 1,355 | 1,276 | |
Misc. Exp. not W/O | 0 | 36 | |||||||||
Total Assets | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,376 | 2,388 | 2,278 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 1,638 | 1,644 | 1,676 | 1,644 | 1,876 | 2,783 | 2,366 | 1,543 | 1,669 | 1,612 | |
Other Income | 13 | 20 | 6 | 23 | 6 | 6 | 4 | 11 | 11 | 25 | |
Total Income | 1,651 | 1,664 | 1,681 | 1,666 | 1,882 | 2,789 | 2,371 | 1,555 | 1,680 | 1,637 | |
Total Expenditure | -1,350 | -1,377 | -1,437 | -1,419 | -1,640 | -2,519 | -2,147 | -1,442 | -1,510 | -1,527 | |
PBIDT | 300 | 287 | 245 | 247 | 242 | 270 | 224 | 113 | 170 | 110 | |
Interest | -138 | -126 | -123 | -117 | -115 | -148 | -126 | -112 | -79 | -77 | |
Depreciation | -84 | -77 | -57 | -62 | -64 | -63 | -61 | -60 | -57 | -59 | |
Taxation | -16 | -18 | -10 | -12 | -10 | -11 | -6 | 12 | -9 | 10 | |
Exceptional Items | -25 | ||||||||||
PAT | 62 | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -16 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | 1 | ||||||||||
Consolidated Net Profit | 62 | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -16 | |
Adjusted EPS | 3 | 3 | 2 | 2 | 2 | 2 | 1 | -3 | 1 | -1 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 361 | 255 | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | |
Cash Fr. Inv. | -99 | -90 | -60 | -77 | -18 | -29 | -26 | -33 | -29 | 17 | |
Cash Fr. Finan. | -282 | -161 | -61 | -89 | -204 | -40 | -201 | -252 | 11 | -119 | |
Net Change | -20 | 4 | 23 | 3 | -23 | -4 | 12 | 0 | 4 | -8 | |
Cash & Cash Eqvt | 6 | 10 | 33 | 37 | 13 | 9 | 21 | 21 | 26 | 18 |
Wed, 15 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Publication of Financial Results of the Company for the quarter ended on December 31 2022 which have been published in the following newspapers:1. Business Standard (English-all editions) dated 15.02.2023.2. Desh Sewak (Punjabi) dated 15.02.2023. |
Tue, 14 Feb 2023
Appointment of Company Secretary and Compliance Officer Appointment of Ms. Neha Vaishnav as the Company Secretary of the Company w.e.f. February 14 2023 |
Tue, 14 Feb 2023
The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Period Ended December 31 2022 The Unaudited Standalone and Consolidated Financial Results for the quarter and nine months period ended December 31 2022 which are enclosed herewith along with the Limited Review Reports of the Auditors thereon. |
Wed, 29 Mar 2023 |
|
|
|
|
|